Skip to main content

Table 2 Changes in estimated fluid volume status at weeks 4, 12, and 24

From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

  Empagliflozin Placebo Group difference (95% CI)
ePV (n)   (n)   
Baselinea 51 2472 ± 382 53 2535 ± 432 − 63 (− 222 to 96)
Change from baseline to 4 weeks, % 44 − 1.19 ± 7.06 45 0.79 ± 9.59 − 1.98 (− 5.54 to 1.57)
Change from baseline to 12 weeks, % 46 − 7.42 ± 9.50 46 0.43 ± 13.35 − 7.85 (− 12.65 to − 3.05)
Change from baseline to 24 weeks, % 48 − 6.66 ± 12.57 52 − 1.13 ± 8.98 − 5.53 (− 9.84 to − 1.22)
eEV
 Baseline, mL 52 13,860 ± 1764 53 14,089 ± 1564 − 228 (− 873 to 416)
 Change from baseline to 4 weeks, mL 45 − 32.4 ± 172.5 47 24.9 ± 153.6 − 57.2 (− 124.8 to 10.4)
 Change from baseline to 12 weeks, mL 46 − 131.2 ± 139.7 48 12.3 ± 166.5 − 143.4 (− 206.5 to − 80.3)
 Change from baseline to 24 weeks, mL 50 − 168.3 ± 202.2 52 − 22.8 ± 218.8 − 145.5 (− 228.4 to − 62.7)
  1. Data are expressed as mean ± SD
  2. CI confidence interval, eEV estimated extracellular volume, ePV estimated plasma volume
  3. aePV at baseline was calculated by the Kaplan-Hakim formula